| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Carcinogenesis |
Division of Nutritional Carcinogenesis, American Health Foundation, Valhalla, New York 10595 [T. K., C. V. R., B. S. R.]; Chemoprevention Branch, National Cancer Institute, Bethesda, Maryland 20892 [R. L., V. E. S., G. J. K.]; and Gene Print, Inc., Bala Cynwyd, Pennsylvania [R. B. K.]
Curcumin, derived from the rhizome of Curcuma longa L. and having both antioxidant and anti-inflammatory properties, inhibits chemically induced carcinogenesis in the skin, forestomach, and colon when it is administered during initiation and/or postinitiation stages. This study was designed to investigate the chemopreventive action of curcumin when it is administered (late in the premalignant stage) during the promotion/progression stage of colon carcinogenesis in male F344 rats. We also studied the modulating effect of this agent on apoptosis in the tumors. At 5 weeks of age, groups of male F344 rats were fed a control diet containing no curcumin and an experimental AIN-76A diet with 0.2% synthetically derived curcumin (purity, 99.9%). At 7 and 8 weeks of age, rats intended for carcinogen treatment were given s.c. injections of azoxymethane (AOM) at a dose rate of 15 mg/kg body weight per week. Animals destined for the promotion/progression study received the AIN-76A control diet for 14 weeks after the second AOM treatment and were then switched to diets containing 0.2 and 0.6% curcumin. Premalignant lesions in the colon would have developed by week 14 following AOM treatment. They continued to receive their respective diets until 52 weeks after carcinogen treatment and were then sacrificed. The results confirmed our earlier study in that administration of 0.2% curcumin during both the initiation and postinitiation periods significantly inhibited colon tumorigenesis. In addition, administration of 0.2% and of 0.6% of the synthetic curcumin in the diet during the promotion/progression stage significantly suppressed the incidence and multiplicity of noninvasive adenocarcinomas and also strongly inhibited the multiplicity of invasive adenocarcinomas of the colon. The inhibition of adenocarcinomas of the colon was, in fact, dose dependent. Administration of curcumin to the rats during the initiation and postinitiation stages and throughout the promotion/progression stage increased apoptosis in the colon tumors as compared to colon tumors in the groups receiving AOM and the control diet. Thus, chemopreventive activity of curcumin is observed when it is administered prior to, during, and after carcinogen treatment as well as when it is given only during the promotion/progression phase (starting late in premalignant stage) of colon carcinogenesis.
This article has been cited by other articles:
|
|
 |
|
  M. Narasimhan and S. Ammanamanchi Curcumin Blocks RON Tyrosine Kinase-Mediated Invasion of Breast Carcinoma Cells Cancer Res., July 1, 2008; 68(13): 5185 - 5192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Vareed, M. Kakarala, M. T. Ruffin, J. A. Crowell, D. P. Normolle, Z. Djuric, and D. E. Brenner Pharmacokinetics of Curcumin Conjugate Metabolites in Healthy Human Subjects Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1411 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Bachmeier, I. V. Mohrenz, V. Mirisola, E. Schleicher, F. Romeo, C. Hohneke, M. Jochum, A. G. Nerlich, and U. Pfeffer Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NF{kappa}B Carcinogenesis, April 1, 2008; 29(4): 779 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Subramaniam, R. May, S. M. Sureban, K. B. Lee, R. George, P. Kuppusamy, R. P. Ramanujam, K. Hideg, B. K. Dieckgraefe, C. W. Houchen, et al. Diphenyl Difluoroketone: A Curcumin Derivative with Potent In vivo Anticancer Activity Cancer Res., March 15, 2008; 68(6): 1962 - 1969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. O. Clarke and G. E. Mullin A Review of Complementary and Alternative Approaches to Immunomodulation Nutr Clin Pract, February 1, 2008; 23(1): 49 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. G. Lin, A. B. Kunnumakkara, A. Nair, W. M. Merritt, L. Y. Han, G. N. Armaiz-Pena, A. A. Kamat, W. A. Spannuth, D. M. Gershenson, S. K. Lutgendorf, et al. Curcumin Inhibits Tumor Growth and Angiogenesis in Ovarian Carcinoma by Targeting the Nuclear Factor-{kappa}B Pathway Clin. Cancer Res., June 1, 2007; 13(11): 3423 - 3430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, B. Ahmed, K. Mehta, and R. Kurzrock Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer Mol. Cancer Ther., April 1, 2007; 6(4): 1276 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Choi, Y.-S. Chun, S.-W. Kim, M.-S. Kim, and J.-W. Park Curcumin Inhibits Hypoxia-Inducible Factor-1 by Degrading Aryl Hydrocarbon Receptor Nuclear Translocator: A Mechanism of Tumor Growth Inhibition Mol. Pharmacol., November 1, 2006; 70(5): 1664 - 1671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Chearwae, S. Shukla, P. Limtrakul, and S. V. Ambudkar Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol. Cancer Ther., August 1, 2006; 5(8): 1995 - 2006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M.R. Patlolla, J. Raju, M. V. Swamy, and C. V. Rao {beta}-Escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21waf1/cip1 in colon cancer cells. Mol. Cancer Ther., June 1, 2006; 5(6): 1459 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Collett and F. C. Campbell Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells Carcinogenesis, June 1, 2006; 27(6): 1285 - 1291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lev-Ari, L. Strier, D. Kazanov, O. Elkayam, D. Lichtenberg, D. Caspi, and N. Arber Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells Rheumatology, February 1, 2006; 45(2): 171 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Shen, C. Xu, R. Hu, M. R. Jain, A. Gopalkrishnan, S. Nair, M.-T. Huang, J. Y. Chan, and A.-N. T. Kong Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin Mol. Cancer Ther., January 1, 2006; 5(1): 39 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lev-Ari, L. Strier, D. Kazanov, L. Madar-Shapiro, H. Dvory-Sobol, I. Pinchuk, B. Marian, D. Lichtenberg, and N. Arber Celecoxib and Curcumin Synergistically Inhibit the Growth of Colorectal Cancer Cells Clin. Cancer Res., September 15, 2005; 11(18): 6738 - 6744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Volate, D. M. Davenport, S. J. Muga, and M. J. Wargovich Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin) Carcinogenesis, August 1, 2005; 26(8): 1450 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Choudhuri, S. Pal, T. Das, and G. Sa Curcumin Selectively Induces Apoptosis in Deregulated Cyclin D1-expressed Cells at G2 Phase of Cell Cycle in a p53-dependent Manner J. Biol. Chem., May 20, 2005; 280(20): 20059 - 20068. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chen and J. Xu Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR Am J Physiol Gastrointest Liver Physiol, March 1, 2005; 288(3): G447 - G456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Garcea, D. P. Berry, D. J.L. Jones, R. Singh, A. R. Dennison, P. B. Farmer, R. A. Sharma, W. P. Steward, and A. J. Gescher Consumption of the Putative Chemopreventive Agent Curcumin by Cancer Patients: Assessment of Curcumin Levels in the Colorectum and their Pharmacodynamic Consequences Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 120 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Collett and F. C. Campbell Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells Carcinogenesis, November 1, 2004; 25(11): 2183 - 2189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Sharma, S. A. Euden, S. L. Platton, D. N. Cooke, A. Shafayat, H. R. Hewitt, T. H. Marczylo, B. Morgan, D. Hemingway, S. M. Plummer, et al. Phase I Clinical Trial of Oral Curcumin: Biomarkers of Systemic Activity and Compliance Clin. Cancer Res., October 15, 2004; 10(20): 6847 - 6854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Moos, K. Edes, J. E. Mullally, and F. A. Fitzpatrick Curcumin impairs tumor suppressor p53 function in colon cancer cells Carcinogenesis, September 1, 2004; 25(9): 1611 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Swamy, I. Cooma, J. M.R. Patlolla, B. Simi, B. S. Reddy, and C. V. Rao Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer prevention and treatment Mol. Cancer Ther., February 1, 2004; 3(2): 215 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Conney Enzyme Induction and Dietary Chemicals as Approaches to Cancer Chemoprevention: The Seventh DeWitt S. Goodman Lecture Cancer Res., November 1, 2003; 63(21): 7005 - 7031. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shishodia, P. Potdar, C. G. Gairola, and B. B. Aggarwal Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-{kappa}B activation through inhibition of I{kappa}B{alpha} kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1 Carcinogenesis, July 1, 2003; 24(7): 1269 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Bharti, N. Donato, S. Singh, and B. B. Aggarwal Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and Ikappa Balpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis Blood, February 1, 2003; 101(3): 1053 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Perkins, R. D. Verschoyle, K. Hill, I. Parveen, M. D. Threadgill, R. A. Sharma, M. L. Williams, W. P. Steward, and A. J. Gescher Chemopreventive Efficacy and Pharmacokinetics of Curcumin in the Min/+ Mouse, a Model of Familial Adenomatous Polyposis Cancer Epidemiol. Biomarkers Prev., June 1, 2002; 11(6): 535 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Fenton, M. S. Wolff, M. W. Orth, and N. G. Hord Membrane-type matrix metalloproteinases mediate curcumin-induced cell migration in non-tumorigenic colon epithelial cells differing in Apc genotype Carcinogenesis, June 1, 2002; 23(6): 1065 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Ireson, D. J. L. Jones, S. Orr, M. W. H. Coughtrie, D. J. Boocock, M. L. Williams, P. B. Farmer, W. P. Steward, and A. J. Gescher Metabolism of the Cancer Chemopreventive Agent Curcumin in Human and Rat Intestine Cancer Epidemiol. Biomarkers Prev., January 1, 2002; 11(1): 105 - 111. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Anto, A. Mukhopadhyay, K. Denning, and B. B. Aggarwal Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl Carcinogenesis, January 1, 2002; 23(1): 143 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Plummer, K. A. Hill, M. F. W. Festing, W. P. Steward, A. J. Gescher, and R. A. Sharma Clinical Development of Leukocyte Cyclooxygenase 2 Activity as a Systemic Biomarker for Cancer Chemopreventive Agents Cancer Epidemiol. Biomarkers Prev., December 1, 2001; 10(12): 1295 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Sharma, H. R. McLelland, K. A. Hill, C. R. Ireson, S. A. Euden, M. M. Manson, M. Pirmohamed, L. J. Marnett, A. J. Gescher, and W. P. Steward Pharmacodynamic and Pharmacokinetic Study of Oral Curcuma Extract in Patients with Colorectal Cancer Clin. Cancer Res., July 1, 2001; 7(7): 1894 - 1900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Collett, C. N. Robson, J. C. Mathers, and F. C. Campbell Curcumin modifies Apcmin apoptosis resistance and inhibits 2-amino 1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) induced tumour formation in Apcmin mice Carcinogenesis, May 1, 2001; 22(5): 821 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Sharma, C. R. Ireson, R. D. Verschoyle, K. A. Hill, M. L. Williams, C. Leuratti, M. M. Manson, L. J. Marnett, W. P. Steward, and A. Gescher Effects of Dietary Curcumin on Glutathione S-Transferase and Malondialdehyde-DNA Adducts in Rat Liver and Colon Mucosa: Relationship with Drug Levels1 Clin. Cancer Res., May 1, 2001; 7(5): 1452 - 1458. [Abstract] [Full Text]
|
|
|
|
|
|
K. Imaida, S. Tamano, K. Kato, Y. Ikeda, M. Asamoto, S. Takahashi, Z. Nir, M. Murakoshi, H. Nishino, and T. Shirai Lack of chemopreventive effects of lycopene and curcumin on experimental rat prostate carcinogenesis Carcinogenesis, March 1, 2001; 22(3): 467 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ireson, S. Orr, D. J. L. Jones, R. Verschoyle, C.-K. Lim, J.-L. Luo, L. Howells, S. Plummer, R. Jukes, M. Williams, et al. Characterization of Metabolites of the Chemopreventive Agent Curcumin in Human and Rat Hepatocytes and in the Rat in Vivo, and Evaluation of Their Ability to Inhibit Phorbol Ester-induced Prostaglandin E2 Production Cancer Res., February 1, 2001; 61(3): 1058 - 1064. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Mariadason, G. A. Corner, and L. H. Augenlicht Genetic Reprogramming in Pathways of Colonic Cell Maturation Induced by Short Chain Fatty Acids: Comparison with Trichostatin A, Sulindac, and Curcumin and Implications for Chemoprevention of Colon Cancer Cancer Res., August 1, 2000; 60(16): 4561 - 4572. [Abstract] [Full Text]
|
|
|
|
|
|
B. S. Reddy Novel Approaches to the Prevention of Colon Cancer by Nutritional Manipulation and Chemoprevention Cancer Epidemiol. Biomarkers Prev., March 1, 2000; 9(3): 239 - 247. [Abstract] [Full Text]
|
|
|
|
|
|
S.E. Chuang, M.L. Kuo, C.H. Hsu, C.R. Chen, J.K. Lin, G.M. Lai, C.Y. Hsieh, and A.L. Cheng Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis Carcinogenesis, February 1, 2000; 21(2): 331 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Reddy, Y. Hirose, R. Lubet, V. Steele, G. Kelloff, S. Paulson, K. Seibert, and C. V. Rao Chemoprevention of Colon Cancer by Specific Cyclooxygenase-2 Inhibitor, Celecoxib, Administered during Different Stages of Carcinogenesis Cancer Res., January 1, 2000; 60(2): 293 - 297. [Abstract] [Full Text]
|
|
|
|
|
|
B. S. Reddy, T. Kawamori, R. A. Lubet, V. E. Steele, G. J. Kelloff, and C. V. Rao Chemopreventive Efficacy of Sulindac Sulfone against Colon Cancer Depends on Time of Administration during Carcinogenic Process Cancer Res., July 1, 1999; 59(14): 3387 - 3391. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
